$0.00
(Market cap
$7 Mln
Recently Viewed
Clear AllMarket cap
$7 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-33 Mln
ROE
-1.4 %
ROCE
-- %
Industry P/E
24.57
EV/EBITDA
0.2
Debt to Equity
1.1
Book Value
$--
EPS
$-0.4
Face value
--
Shares outstanding
67,715,696
CFO
$-317.45 Mln
EBITDA
$-349.75 Mln
Net Profit
$-345.89 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aptinyx (APTX)
| -66.9 | 53.6 | 41.2 | -66.9 | -70.5 | -64.3 | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
Aptinyx (APTX)
| -66.9 | -89.1 | -22.8 | 1.2 | -79.3 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aptinyx (APTX)
|
0.1 | 6.5 | 0.0 | -29.2 | -- | -87 | -- | 0.4 |
| 12.4 | 3,993.9 | 3,018.8 | 72.1 | 12.6 | -80 | 56.9 | 105.4 | |
| 40.9 | 5,228.7 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.2 | 14.1 | |
| 187.9 | 9,667.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 109.5 | |
| 73.8 | 14,879.0 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.1 | 4,910.2 | 761.4 | 99.7 | 7.3 | 15 | 56.3 | 7.6 | |
| 22.4 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 8.1 | 7,186.6 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.5 | 1.0 | |
| 226.6 | 4,622.8 | 268.1 | 124.5 | 60.0 | 13.5 | 37.8 | 4.4 | |
| 61.4 | 3,667.1 | 391.6 | -76.6 | -19.3 | -16.4 | -- | 8.0 |
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product... candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois. Read more
Exec. Chairman
Dr. Norbert G. Riedel
Exec. Chairman
Dr. Norbert G. Riedel
Headquarters
Evanston, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Aptinyx Inc (APTX) is $0.10 (NASDAQ) as of 29-Dec-2023 15:59 EDT. Aptinyx Inc (APTX) has given a return of -70.48% in the last 3 years.
Since, TTM earnings of Aptinyx Inc (APTX) is negative, P/E ratio is not available.
The P/B ratio of Aptinyx Inc (APTX) is 0.36 times as on 29-Dec-2023, a 94 discount to its peers’ median range of 5.70 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.31
|
0.51
|
|
2021
|
-2.43
|
1.91
|
|
2020
|
-4.10
|
1.40
|
|
2019
|
-2.02
|
1.14
|
|
2018
|
-10.33
|
3.69
|
The 52-week high and low of Aptinyx Inc (APTX) are Rs -- and Rs -- as of 25-Apr-2026.
Aptinyx Inc (APTX) has a market capitalisation of $ 7 Mln as on 29-Dec-2023. As per SEBI classification, it is a company.
Before investing in Aptinyx Inc (APTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.